Selling, Cold Calling, and Follow-Up Are Not Dirty Words

13 May

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

The coaching and mentoring universe is divided between those who think that selling, cold calling, and follow-ups are dirty words. They’re likely to proselytize that if you do not have a warm referral, you are wasting your time. The other camp (where I live) supports finding partners based on the fit of product and stage of development and reaching out until you book that meeting or are told, “No.” Life Science Nation created the RESI conference to be a vehicle to make this happen, based on fit – the other “warm referral.”

Opportunity abounds in the golden age of life science with new tools and technologies adding to the dynamic, but we’re also seeing startups fail faster, and therefore pivot, restart, and draw a straighter line to viable targets and products. I hear frequently that the magic combination is being smart and lucky, but somewhere in the middle of being smart and lucky is determination, commitment to hard, tedious work, and navigating the path to a new product. This is the case for founders taking their companies from regional to global and finding investors and licensing partners that are a fit.

RESI is a conference designed for these entrepreneurs to flourish. It’s frustrating to see partnering events with little vetted investors or licensing partners, but rather services providers wanting to charge for their partnering services. These other partnering events are more of a social gathering for reconnecting business acquaintances, which makes it a challenge in choosing the right event for you. None of this is inherently wrong, but the current need is for real vetted partners who are looking to fulfil investment mandates and product pipelines.

The early-stage marketplace is heating up with growing buy-side players seeking these startups. Join us for Digital RESI, June 7-9 and mark your calendar for the first in-person RESI since 2020 – RESI Boston, September 21-22.

Book Meetings, Form Partnerships, Save the World

12 May

By Karen Deyo, Director of Investor Research, Israel BD, LSN

The time has come to launch the partnering platform for Digital RESI, June 7-9. Launching on Monday, May 16, the partnering platform – powered by the LSN Investor Database – enables companies to identify investors and strategic partners who are a fit for their sector, product, and stage of development, among other important criteria.

Using the partnering platform to its fullest capacity can seem like a daunting task, and it is a lot of hard work! We have compiled a lot of tips and tricks to help companies get the most out of their partnering experience. Check out the links below.

Still have questions? Our business development team is happy to aid and answer any questions!

Want to learn more? The Business Development team at Life Science Nation is available to answer questions and share additional details to help you meet your partnership goals!
International
East Coast (USA) & China
Midwest (USA)
& Canada
West Coast  (USA)
Alex
Greg Mannix
Vice President International Business Development
Book a Meeting
Email Me
Candice He
VP, Business Development & Global Investment Strategist
Book a Meeting
Email Me
Antoinette Lowre
Manager of Business Development
Book a Meeting
Email Me
Alexander Vassallo
Manager of Business Development
Book a Meeting
Email Me

The Story of Innovator’s Pitch Challenge

12 May

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claire

Just as a good story is the backbone to any pitch, so the story behind the Innovator’s Pitch Challenge (IPC) explains why it has become a RESI mainstay and one of the event’s most popular sessions with both startups and investors alike. Prior to the Covid-19 global pandemic, pitch sessions were included in the RESI agendas, but not met with the same enthusiasm we now see. In early 2020, the entire life science industry scrambled to figure out how to best adjust and shift perspectives and workflow.

As the world came to a halt, RESI had to pivot, and we reassessed how to best add value to the growing need for early-stage technology assets in life science and healthcare. Pitching is necessary for startups to share their story and increase their exposure to investors and other relevant industry experts. However, there is often a noticeable lack of engagement. At other conferences, we saw companies that had dedicated hours and days to practicing and perfecting their pitch got little value-add beyond the single encounter. Adding this value to a virtual format became our singular goal.

The IPC is unique in that all companies have a dedicated landing page where they can share any relevant company materials, viewable by all conference attendees. All IPC finalists are assigned to a live Q&A session with investor and industry expert judges who actively work with companies in their sector and stage of development and receive early access to each company’s marketing materials, which allows for more targeted, detailed questions. These judges often self-select, so they participate with genuine interest in the participating companies. See what judges have had to say about their participation:

“The Pitch Sessions were a great opportunity to engage with the CEO/Founders of very innovative Life Science startups. Despite the COVID-related transition from in-person to virtual meetings, the RESI team did an outstanding job organizing these sessions, ensuring that the live Q&A was very productive, and facilitating follow-up with these exciting companies.”


Gary Gershony, Life Science Angels / BayMed Venture Partners

 


“The Pitch Sessions are a great opportunity to connect with startup CEOs and learn more about their work…It really has been an effective and efficient way to make connections, create deal flow and help startups raise money for their upcoming raises.”

Mayank Taneja, OSF Healthcare

“It was a very economical use of time; the investors got to ask their important questions and the Innovators got a good idea of the most pressing questions from the investors point of view.”


William Kuziel, MedPro Investors
To date, 700+ companies applied to present and 300+ unique investors and industry expert judges have participated in the live pitch sessions. Join the companies featured below and apply to pitch at Digital RESI, June 7-9 by Friday, May 13!

Hot Investor Mandate: VC Firm With Strong China Expertise Invests in Global Novel Therapeutics Addressing Unmet Need, from Seed to Growth Stage

12 May

A life science venture capital firm with strong China expertise and global capabilities. Founded in 2017, the firm discovers, incubates and grows next-generation life science companies in early and growth stage, worldwide. Their portfolio companies pioneer differentiated therapies and enabling technologies to address major human diseases with high unmet medical needs. They operate offices in Boston, Shanghai, as well as Palo Alto.

The firm focuses mostly on novel therapeutics, like small molecule, cell therapy, gene therapy, etc, while the firm is also open to enabling technologies and high-end specialty services. The firm is looking to invest from seed, first institutional round, to growth stage.

The firm has no specific requirement for the company & management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Major Financial Institution with Billions in AUM Actively Seeks Therapeutics and Medical Device Investment Opportunities, Mostly in Europe

12 May

A major financial institution based in Western Europe managing venture capital funds totaling to several billion, is significantly focused on life sciences. The firm both invests in venture capital funds and makes direct investments in seed-stage and early-stage companies. Typically the firm invests EUR 0.5-8 million initially, with further capital reserved for follow-on rounds. The firm primarily invests in companies in Europe.

The firm is interested in opportunities in biotech and medical devices, and may potentially invest in digital health. The firm is not interested in diagnostics. The firm has a broad interest in early stage therapeutics (mainly First-In-Class), including small molecules, biologics, cell and gene therapies, and all indication areas including cardiovascular, neurology, and rare diseases. The firm invests from preclinical-stage companies through to Phase II.

The firm prefers to invest in companies based in the country where their headquarters are located, but will consider opportunities elsewhere in Europe: for companies in this country, the firm is typically a lead or co-lead investor, but in other regions the firm prefers to be a follow-on investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Asia-Based Pharmaceutical Seeks In-Licensing and Collaboration Opportunities With Promising Technologies in Pain and Inflammatory Diseases

12 May

A pharmaceutical company dedicated to research, development, and commercialization of innovative products for unmet medical needs in the areas of musculoskeletal disorders, including pain management and critical care, is vastly investing to expand their presence from its domestic roots to become a Global Specialty Pharma. To achieve above goal, the firm is looking for opportunities of early stage pipelines and/or research collaborations with global rights to expand their business worldwide.

The firm Is pursuing attractive, new in-licensing and research collaboration opportunities in the following areas of interest: in relation to in-licensing opportunities in pre-clinical stage for the global market, the firm is interested in chronic pain, inflammatory diseases (including rheumatoid arthritis), critical care, and muscle-related disorders (i.e. DMD, ALS, etc.) In relation to research collaboration opportunities for the global market, the firm is interested in drug seeds for chronic pain, inflammatory diseases (including rheumatoid arthritis), critical care, as well as platform technologies related to drug delivery, formulation, excipients, oral, transdermal, nanoparticle, controlled release, and targeting.

The firm has no specific company or management team requirements and is willing to work with all early-stage companies globally, with promising technologies. The firm will seek global rights.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Therapeutics Accelerator Actively In-Licenses Assets from Pre-Clinical to Early Clinical Stages of Development, Considering Opportunities Across All Modalities

12 May

A therapeutic accelerator looks to in-license therapeutics assets from inventors/founders, and fund the assets’ development through clinical proof-of-concept. The firm is looking for assets throughout the United States and is actively seeking new opportunities. The firm has signed a partnership with a major VC firm, who will advise on current and future investments.

The firm is currently looking for therapeutic assets in pre-clinical through early clinical stages of development. The firm is open in terms of indication and will consider both small molecules and biologics, and will also consider drug repurposing opportunities. The firm looks to in-license these assets and accelerate their development through to clinical proof-of-concept, at which point the firm looks to partner the asset with pharmaceutical firms or other investors who will complete the commercialization of the asset. The firm has signed strategic partnerships with major pharma, regarding products in cardiovascular, metabolic, neuroscience, and immunology indications.

The firm focuses on the strength of the technology when evaluating in-licensing opportunities. The company leverages a capable and connected team and advisors for the development, funding, active management, and partnering of its portfolio of therapeutic products.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: